Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
My lab, broadly speaking, is interested in trying to understand interactions between cells and materials. Those could be materials that are present within living tissue or materials that we use for engineering purposes to try to do something of technological or therapeutic interest.
Glioblastoma is the most aggressive cancer that originates in the brain. Current therapies can slow the disease, but more often than not can't cure it.
Glioblastoma is the most common of malign brain tumors in adults, and it currently has no cure. Now a research team led by Dr Claudia Barros, from the Plymouth University Peninsula Schools of Medicine and Dentistry and its Brain Tumour Research-funded Centre of Excellence, has secured funding from the Brain Research Trust, which will help to expose novel molecules and their modes of action responsible for the initiation and growth of the disease.
Scientists at the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions including Colorado State University and Fred Hutchinson Cancer Center reported results today from a glioblastoma study in which they validated a biomarker indicative of a patient's prognosis and likely response to specific therapies.
UCLA scientists have discovered a potential combination treatment for glioblastoma, the deadliest form of brain cancer in adults. The three-year study led by Dr. David Nathanson, a member of UCLA's Jonsson Comprehensive Cancer Center, found that the drug combination tested in mice disrupts and exploits glucose intake, essentially cutting off the tumor's nutrients and energy supply.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells to evade the immune system.
The largest genomic profiling study ever conducted into a type of brain tumor known as glioma in children has identified genetic alterations in 96% of cases. As reported in The Oncologist, this genetic information could help to identify the most effective treatments for specific cases of glioma, hopefully improving the prognosis for what is currently the leading cause of death for children with cancer in the US.
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Patients diagnosed at high-volume centers are up to 40 percent more likely to receive treatment for glioblastoma, according to a study from researchers at the University of Illinois at Chicago.
According to a latest study supported by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, the deadly Zika virus could be used to kill a specific type of brain cancer cells and sparing the neighbouring healthy brain cells. Although experimental in stage, this finding has wide implications for those suffering from these cancers.
While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer.
Pioneering charity Brain Tumour Research has been awarded a £150,000 grant over three years by London Freemasons.
The most aggressive variant of brain tumor - glioblastoma - has an average survival rate of 15 months. There is therefore an urgent need for new treatment strategies for this group of patients.
Moffitt Cancer Center and Cvergenx announced a new research partnership that aims to revolutionize radiation therapy. The goal of the Future of Radiation Therapy project is to create a framework for using a patient's genetic information to provide a personalized radiation treatment plan.
Patients undergoing conventional chemotherapy for certain cancers could potentially receive more effective and less toxic drug treatment.
The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at Roswell Park Cancer Institute.
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy, and radiation.
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment.
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease.